Company Overview
About ROME Therapeutics
ROME Therapeutics is a Cambridge, Massachusetts-based biopharmaceutical company pioneering a novel approach to drug discovery by targeting the "dark genome" — the vast portion of the human genome composed of repetitive DNA sequences that has historically been ignored or considered non-functional. ROME''s scientific hypothesis is that specific classes of genomic repeats, particularly LINE-1 (Long Interspersed Nuclear Elements) retrotransposons, become aberrantly activated in diseased cells — including cancer cells and cells involved in autoimmune disorders — and drive disease pathology through mechanisms distinct from traditional drug targets.
Business Model & Competitive Advantage
ROME has attracted nearly $200 million in total funding, including a $149 million Series B that saw rare pharma strategic investment: Johnson & Johnson, Bristol Myers Squibb, Sanofi, Eurofarma Ventures, Mirae Asset Capital, Luma Group, and ARCH Venture Partners all participated. This strategic investor consortium reflects the pharmaceutical industry''s growing conviction that dark genome biology represents a major untapped therapeutic opportunity. ROME''s lead program is a small-molecule inhibitor of LINE-1 reverse transcriptase, targeting the enzyme these retrotransposons use to proliferate in disease states. This program is advancing toward first-in-human trials as a treatment for lupus and other interferon-driven autoimmune diseases.
Competitive Landscape 2025–2026
In late 2025, ROME refocused its pipeline on autoimmune and neurodegenerative diseases, deprioritizing certain oncology programs, and made staff reductions to extend its financial runway through clinical proof-of-concept. The company continues to co-host the annual Dark Genome Symposium with Enara Bio, positioning itself as the scientific hub for an emerging field that multiple large pharmaceutical companies are beginning to explore.
Key Differentiators
Strong Challenger
ROME Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Cradle
Cradle is a protein design platform using AI to help biotechnology and pharmaceutical companies engineer better proteins — enzymes, antibodies, and therapeutic proteins — with improved stability, acti
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Compare ROME Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from ROME Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim ROME Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention ROME Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →